🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Canada / NCT06522061
Starting soon Not applicable

Evaluating the Effective and Safe Use of Stream™ Platform

NCT06522061 · tracked via the Priya Life Science Canada tracker
Phase
Not applicable
Started
2025-03-15
Last updated
2025-02-28

Condition(s) studied

User-Centered DesignAnastomotic LeakColorectal SurgeryArtificial Intelligence

Investigational drug(s) / intervention(s)

Stream™ Platform

Stream™ Platform: Stream™ Platform consists of 5 main components: Origin™, Delta™ Monitor, Stream™ Application, Accessory Calibration Syringe(s), and Stream™ Cart. Origin™ is an inline biosensor system that can be attached between an off-the-shelf drainage catheter and evacuator bag/bulb system and is designed to monitor real-time changes in drained effluent characteristics (specifically pH and electrical conductivity (EC)) for the early identification of postoperative complications. Origin™ requires daily calibration (via Accessory Calibration Syringe(s)) for optimal performance and accuracy of its sensors. The Stream Application is a mobile application for displaying and analyzing data collected continuously via Origin™. Stream™ Application is pre-installed on Android mobile devices (called Delta™ Monitor) that are supplied by FluidAI. Origin connects to Stream Application via Bluetooth. Mobile carts/mounts, denoted Stream™ Carts/Delta Mounts, will be used to house the Delta™ Monitor.

Study summary

The study aims to demonstrate the potential for at-home monitoring using Stream™ Platform, through simulated-use testing. Lay users, defined as subjects or nonprofessional caregivers, will be asked to operate Stream™ Platform. Safety, efficacy, and usability data will be collected to ensure that users are able to comply with prescribed device use.

Additionally, clinical testing will be conducted to identify correlations between measurements from Stream™ Platform and standard laboratory, radiological, and clinical assessments used for leak detection as part of the current standard of care (SOC) that may be skipped if the subject is discharged early.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥ 18 years - male or female. * Subject/SDM understands and has voluntarily signed and dated Informed Consent Form (ICF). * Subject underwent colorectal surgery with anastomosis. * Subjects must be willing to comply with trial requirements. * Subject has a prophylactic abdominal/pelvic drain after colorectal surgery. Exclusion Criteria: * Subjects/caregiver is unwilling or unable to comply with the requirements of the protocol. * 24 hours or more have passed since the end of the subject's surgery and consent was not attained. * The subject had already developed an anastomotic leak at the time of screening and underwent surgery for treatment of the complication. * Plans that the subject will be discharged in less than 3 days post-surgery. * Subject has reported that they are pregnant. * Subject has a permanent end stoma. * Subject is delirious. * Subject has severe dementia. * Subject was involved in the planning and conduct of the clinical investigation. * Origin™ is not compatible with the drain used on the subject. * Subject and/or caregiver is/are not capable of conducting the calibrations for Stream™ Platform (this can be self-reported or determined by the CRC/HCP/other research staff). * The subject and/or caregiver is/are unable to understand the instructions provided for the management and calibration of Stream™ Platform (this can be self-reported or determined by the CRC/investigator/other research staff).

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
St. Paul's Hospital - Providence Healthcare (PHC) Vancouver British Columbia

More FluidAI Medical trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06522061 on ClinicalTrials.gov ↗ ← All trials in Canada